Newer Att Flashcards
1
Q
Delamanid Family Moa Company Launched Dose
A
Notroimidazole Cidal Inhibit ma synthesis / no Otsuka pharma 2017 100 bd for 24 wks
2
Q
Inclusion criteria
A
Not eligible for shorter regimen. Non pregnant Stable arrythmia No electrolyte imbalnce >2.8G/DL S.ALBUMIN
3
Q
Mutations
A
Fbi a,b,c
4
Q
Dose
A
6-11 50 bd
12- 100 bd
5
Q
Trails
A
Endtb
Deliberate
Otsuka 213,1233
6
Q
Bedaquiline
Family
Moa
A
Diarylquinolone
Atp synthesis blocker
Cidal
7
Q
Trail of bdq
A
Tmc 207
8
Q
Exclusion criteria bdq
A
Uncontrolled arrythmia Qtc prolonged Creat 1.5 , hb6.5 , plat 50000, lft deranged Hf Hypokalemia Long qt history
9
Q
Dose bdq
A
400 od 2wks
3-24 wks 200 thrice weekly
With meals
10
Q
Management in adverse effects
A
Hepatotoxic- 1,2- continue
3,4- withhold and start
Pancreatitis- 1 and 2- up to 2 times uln- continue
3 and 4 - 2 to 5 or more- d/c
11
Q
Linid Family Moa Dose Side effects
A
Oxazolidone Inhibit protein synthesis- binds to 23s portion of 50s subunit Non selective , reversible mao inhibitor 16-29 kg- 300mg 30- 600 Children- 10mg/kg max 600
12
Q
Spectrum of linid
A
Positive , strep , vre , mrsa , mssa, mdr/xdr
13
Q
Side effects of linid
A
Optic and peripheral neuropathy Bm suppression Seritonin syndrome Cheese rxn Lactic acidosis
